国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2013年
3期
167-171
,共5页
肝肿瘤%肝炎%乙型%经导管肝动脉节段性化疗栓塞%经导管肝动脉化疗栓塞
肝腫瘤%肝炎%乙型%經導管肝動脈節段性化療栓塞%經導管肝動脈化療栓塞
간종류%간염%을형%경도관간동맥절단성화료전새%경도관간동맥화료전새
Liver neoplasms%Hepatitis B%Transcatheter arterial segmental chemoembolization%Transcatheter arterial chemoembolization
目的 分析比较乙型肝炎(乙肝)后原发性肝癌治疗中经导管肝动脉节段性化疗栓塞(TASCE)和经导管肝动脉化疗栓塞(TACE)疗效及对肝功能的影响.方法 回顾性选取乙肝后原发性肝癌患者80例,其中行TACE和TASCE治疗各40例,检测其术后1天、术后1周和术后4周血清ALT、AST、TBil和白蛋白(ALB)指标,电子计算机X射线断层扫描技术(CT)检测其术后1月的肿瘤缩小率.结果 ALT分析:TACE组术后1天、术后1周、术后4周分别为(515.25±107.34)、(196.80±64.33)、(65.52±10.20) U/L,高于ASCE组的(117.51±21.47)、(82.13±28.31)、(58.38±8.34) U/L,差异具有显著统计学意义(t=22.98,P＜0.01;t=10.32,P＜0.01;t=3.43,P＜0.01);AST 分析:TACE组术后1天、术后1周、术后4周分别为(454.58±83.09)、(68.72±8.13)和(43.62±6.43) U/L,高于TASCE组的(123.51±19.32)、(48.68±6.57)和(39.54±5.12) U/L,差异具有显著统计学意义(t=24.55,P＜0.01;t=12.13,P＜ 0.01;t=3.14,P＜0.01);TBil分析:TACE组术后1天、术后1周、术后4周分别为(51.97±6.23)、(35.74±4.56)和(20.04±3.81) μmol/L,高于TASCE组的(25.36±3.11)、(23.65±3.21)和(16.75±1.89) μmol/L,差异具有显著统计学意义(t=24.17,P＜0.01;t=13.73,P＜0.01;t=4.89,P＜0.01);ALB分析:TACE组术后1天、术后1周、术后4周分别为(33.54±3.56)、(30.74±3.12)和(32.78±4.11) g/L,低于TASCE组的(37.67±5.34)、(36.95±3.60)和(38.23±3.68) g/L,差异具有显著统计学意义(t=-4.06,P＜0.01;t=-8.24,P＜0.01;t=-6.25,P＜ 0.01).密实型碘油沉积形态肿瘤中,TACE组肿瘤缩小率(50.00％)低于TASCE组(86.36％),差异具有显著统计学意义(x2=5.96,P＜0.05).结论 在乙肝后原发性肝癌治疗中,TASCE方式的疗效和护肝作用明显优于TACE方式.
目的 分析比較乙型肝炎(乙肝)後原髮性肝癌治療中經導管肝動脈節段性化療栓塞(TASCE)和經導管肝動脈化療栓塞(TACE)療效及對肝功能的影響.方法 迴顧性選取乙肝後原髮性肝癌患者80例,其中行TACE和TASCE治療各40例,檢測其術後1天、術後1週和術後4週血清ALT、AST、TBil和白蛋白(ALB)指標,電子計算機X射線斷層掃描技術(CT)檢測其術後1月的腫瘤縮小率.結果 ALT分析:TACE組術後1天、術後1週、術後4週分彆為(515.25±107.34)、(196.80±64.33)、(65.52±10.20) U/L,高于ASCE組的(117.51±21.47)、(82.13±28.31)、(58.38±8.34) U/L,差異具有顯著統計學意義(t=22.98,P＜0.01;t=10.32,P＜0.01;t=3.43,P＜0.01);AST 分析:TACE組術後1天、術後1週、術後4週分彆為(454.58±83.09)、(68.72±8.13)和(43.62±6.43) U/L,高于TASCE組的(123.51±19.32)、(48.68±6.57)和(39.54±5.12) U/L,差異具有顯著統計學意義(t=24.55,P＜0.01;t=12.13,P＜ 0.01;t=3.14,P＜0.01);TBil分析:TACE組術後1天、術後1週、術後4週分彆為(51.97±6.23)、(35.74±4.56)和(20.04±3.81) μmol/L,高于TASCE組的(25.36±3.11)、(23.65±3.21)和(16.75±1.89) μmol/L,差異具有顯著統計學意義(t=24.17,P＜0.01;t=13.73,P＜0.01;t=4.89,P＜0.01);ALB分析:TACE組術後1天、術後1週、術後4週分彆為(33.54±3.56)、(30.74±3.12)和(32.78±4.11) g/L,低于TASCE組的(37.67±5.34)、(36.95±3.60)和(38.23±3.68) g/L,差異具有顯著統計學意義(t=-4.06,P＜0.01;t=-8.24,P＜0.01;t=-6.25,P＜ 0.01).密實型碘油沉積形態腫瘤中,TACE組腫瘤縮小率(50.00％)低于TASCE組(86.36％),差異具有顯著統計學意義(x2=5.96,P＜0.05).結論 在乙肝後原髮性肝癌治療中,TASCE方式的療效和護肝作用明顯優于TACE方式.
목적 분석비교을형간염(을간)후원발성간암치료중경도관간동맥절단성화료전새(TASCE)화경도관간동맥화료전새(TACE)료효급대간공능적영향.방법 회고성선취을간후원발성간암환자80례,기중행TACE화TASCE치료각40례,검측기술후1천、술후1주화술후4주혈청ALT、AST、TBil화백단백(ALB)지표,전자계산궤X사선단층소묘기술(CT)검측기술후1월적종류축소솔.결과 ALT분석:TACE조술후1천、술후1주、술후4주분별위(515.25±107.34)、(196.80±64.33)、(65.52±10.20) U/L,고우ASCE조적(117.51±21.47)、(82.13±28.31)、(58.38±8.34) U/L,차이구유현저통계학의의(t=22.98,P＜0.01;t=10.32,P＜0.01;t=3.43,P＜0.01);AST 분석:TACE조술후1천、술후1주、술후4주분별위(454.58±83.09)、(68.72±8.13)화(43.62±6.43) U/L,고우TASCE조적(123.51±19.32)、(48.68±6.57)화(39.54±5.12) U/L,차이구유현저통계학의의(t=24.55,P＜0.01;t=12.13,P＜ 0.01;t=3.14,P＜0.01);TBil분석:TACE조술후1천、술후1주、술후4주분별위(51.97±6.23)、(35.74±4.56)화(20.04±3.81) μmol/L,고우TASCE조적(25.36±3.11)、(23.65±3.21)화(16.75±1.89) μmol/L,차이구유현저통계학의의(t=24.17,P＜0.01;t=13.73,P＜0.01;t=4.89,P＜0.01);ALB분석:TACE조술후1천、술후1주、술후4주분별위(33.54±3.56)、(30.74±3.12)화(32.78±4.11) g/L,저우TASCE조적(37.67±5.34)、(36.95±3.60)화(38.23±3.68) g/L,차이구유현저통계학의의(t=-4.06,P＜0.01;t=-8.24,P＜0.01;t=-6.25,P＜ 0.01).밀실형전유침적형태종류중,TACE조종류축소솔(50.00％)저우TASCE조(86.36％),차이구유현저통계학의의(x2=5.96,P＜0.05).결론 재을간후원발성간암치료중,TASCE방식적료효화호간작용명현우우TACE방식.
Objective To investigate the clinical effects of transcatheter arterial chemoembolization(TACE) and transcatheter arterial segmental chemoembolization(TASCE) on treatment of primary liver cancer.Methods Eighty patients of liver cancer after hepatitis B were selected retrospectively.Forty patients were treated with TACE and 40 patients with TASCE.Their serum levels of ALT,AST,TBil,ALB at 1 day after the surgery,1 week after the surgery,4 week after the surgery were detected.Rates of tumor shrinkage were calculated by CT a month after the surgery.Results Serum levels of ALT in TACE group one day after surgery,one week since surgery,4 weeks since surgery were (515.25 ±107.34),(196.80 ± 64.33) and (65.52 ± 10.20) U/L,and were significantly higher than those in TASCE group [(117.51±21.47),(82.13±28.31)and (58.38±8.34)U/L,separately](t =22.98,P＜0.01; t =10.32,P＜ 0.01 ; t =3.43,P ＜ 0.01).Serum levels of AST in TACE group one day after surgery,one week since surgery,4 weeks since surgery were (454.58 ± 83.09),(68.72 ± 8.13) and (43.62 ± 6.43) U/L,and were significantly higher than those in TASCE group[(123.51 ± 19.32),(48.68 ± 6.57) and (39.54 ± 5.12) U/L,(sep tely)] (t =24.55,P ＜ 0.01; t =12.13,P ＜ 0.01; t =3.14,P ＜ 0.01).Serum levels of TBil in TACE group on the day after surgery,after a week since surgery,after 4 weeks since surgery were (51.97 ± 6.23),(35.74 ± 4.56) and (20.04 ± 3.81) μmol/L,and were significantly higher than those in TASCE group[(25.36 ± 3.11),(23.65 ± 3.21) and (16.75 ± 1.89) μmol/L,separately] (t =24.17,P ＜ 0.01; t =13.73,P ＜ 0.01; t =4.89,P ＜ 0.01).Serum levels of ALB in TACE group on the day after surgery,one week since surgery,4 weeks since surgery were (33.54 ± 3.56),(30.74±3.12) and (32.78±4.11) g/L,and were significantly lower than them in TASCE group[(37.67 ±5.34),(36.95±3.60) and (38.23±3.68)g/L,separately](t =-4.06,P＜0.01; t =-8.24,P＜0.01; t =-6.25,P＜0.01).In the type of tumor with morphology of dense iodine oil,rate of tumor shrinkage in TASCE group(86.36％) was significantly higher than TACE group(50.00％) (x2=5.96,P＜0.05).Conclusions In clinical treatment for primary liver cancer,clinical effects and hepatoprotection of TASCE group are hbtter than TACE group.
